The Pharmaceutical Journal
Vol 273 No 7329 p840
11 December 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Sativex delayed by CSM

More evidence of the effectiveness of Sativex, GW Pharmaceuticals’s cannabis-derived treatment for spasticity in multiple sclerosis, has been demanded by the Committee on Safety of Medicines.

GW is to carry out further studies, as requested, but also intends to appeal to the Medicines Commission for the granting of a product licence on the basis of the current evidence.